Anixa Biosciences(ANIX) - 2025 Q2 - Quarterly Report

Revenue - No revenue was generated during the three-month and six-month periods ended April 30, 2025 and 2024[84][92] Expenses - Research and development expenses decreased by approximately $324,000 to approximately $1,322,000 in the three months ended April 30, 2025, compared to approximately $1,646,000 in the same period of 2024[87] - General and administrative expenses decreased by approximately $140,000 to approximately $1,681,000 in the three months ended April 30, 2025, from approximately $1,821,000 in the same period of 2024[88] - Research and development expenses for cancer vaccines and CAR-T therapeutics were approximately $1,873,000 and $1,001,000, respectively, during the six months ended April 30, 2025[94] - General and administrative expenses decreased by approximately $566,000 to approximately $3,515,000 in the six months ended April 30, 2025, from approximately $4,081,000 in the same period of 2024[96] Income - Interest income decreased by approximately $96,000 to approximately $190,000 in the three months ended April 30, 2025, from approximately $287,000 in the same period of 2024[89] - Interest income decreased by approximately $243,000 to approximately $363,000 in the six months ended April 30, 2025, from approximately $606,000 in the same period of 2024[97] Assets and Cash Flow - Total current assets decreased by approximately $4,596,000 to approximately $16,766,000 at April 30, 2025, compared to approximately $21,362,000 at October 31, 2024[100] - Cash used in operating activities was approximately $4,407,000 during the six months ended April 30, 2025[101] Net Loss - The net loss attributable to noncontrolling interest decreased by approximately $24,000 to approximately $52,000 in the six months ended April 30, 2025, from approximately $76,000 in the same period of 2024[98] Internal Controls - There was no change in internal control over financial reporting during the three months ended April 30, 2025, that materially affected internal control[117] - The Chief Executive Officer and Chief Financial Officer concluded that disclosure controls and procedures are effective as of the end of the reporting period[116] Compensation Allocation - The company allocates certain internal compensation costs to research and development expenses based on management's estimates of employee time and effort[113]